Denmark is one of the world’s top pharmaceutical manufacturing countries.
Its pharmaceutical industry employs about 70,000 people and accounts for about 15% of the country’s GDP.
But its government has long been criticized for its lack of transparency.
Now, the Danish government is rolling out a new system to ensure that its pharmaceutical products get the most out of the resources it has at its disposal.
Denmark’s new program will allow manufacturers to submit their products for approval before they’re sent out to the marketplace.
The system will give manufacturers a much-needed opportunity to see what they can do to get their drugs into the hands of the patients they’re intended to help.
For years, manufacturers have been forced to pay higher prices than they were willing to pay for the same level of quality and innovation.
Danish manufacturer Algolia has been one of those companies.
“Our manufacturers are very sensitive to quality and we’re very, very focused on quality,” said Algolian CEO Løren Møller.
Møller has been a longtime advocate of transparency in the Danish pharmaceutical industry.
He’s seen the value in keeping his suppliers informed about their products and working to improve the process so that he can offer the highest quality.
Since 2011, Møllers company has developed a program called “SVOPs” that helps manufacturers test their products before they leave Denmark.
Companies with SVOPs can submit their own tests before they send out their products to the market.
And those tests can be used to see how they compare to the quality standards in the U.S. and other countries that have taken a tougher stance on drug safety.
The first SVOP is set to go live in 2019.
It will be a test that will compare Algolis’ drugs with a list of pharmaceuticals produced in the United States.
The SVOP system has been in place for about two years and will be updated regularly, said Albieta Støjberg, a research fellow at the Danish Academy of Sciences.
When it comes to SVOP, Möller said it’s important to be aware of the fact that it’s a “test” rather than a clinical trial.
Algolia is one company that will be able to participate in the program.
Algols main competitors in the SVOP program are Pfizer and Merck.
Both companies are large pharmaceutical companies that produce a lot of their drugs in Europe.
Algom’s main competitor in the company’s market is Gilead, which produces vaccines and immunizations in Europe and the United Kingdom.
Møls study found that SVOP would also be beneficial for Algoli because it will help its product be more competitive in the market for pharmaceuticals.
Algolians SVOP test will include an analysis of Algos vaccines and other pharmaceuticals, as well as tests that will give the manufacturer a better idea of the effectiveness of the vaccines.
The test is expected to take about four weeks to complete.
Algo and Algoma, which are the two other major Danish pharmaceutical companies, are not part of the program, and the companies have not commented on whether they will participate.